BAKER BROS. ADVISORS LP Q1 2020 Filing
Filed May 15, 2020
Portfolio Value
$16.2B
Holdings
110
Report Date
Q1 2020
Filing Type
13F-HR
All Holdings (110 positions)
| Stock | Value |
|---|---|
SGENEURSeattle Genetics, Inc. | $5.8B |
INCYIncyte Corporation | $2.3B |
ACADACADIA Pharmaceuticals Inc. | $1.8B |
ONCBeiGene, Ltd. | $1.4B |
ALXNAlexion Pharmaceuticals, Inc. | $786.6M |
BMRNBioMarin Pharmaceutical Inc. | $641.3M |
KODKodiak Sciences Inc. | $552.1M |
ASNDAscendis Pharma A/S | $381.8M |
1K0IGM Biosciences, Inc. | $176.5M |
AMRNAmarin Corporation plc | $138.0M |
ARGXargenx SE | $134.3M |
NVTA1EURInvitae Corporation | $124.4M |
—Principia Biopharma Inc. | $116.1M |
MRTXEURMirati Therapeutics, Inc. | $108.4M |
NBIXNeurocrine Biosciences, Inc. | $107.3M |
EXASExact Sciences Corporation | $107.1M |
—Ra Pharmaceuticals, Inc. | $100.5M |
MDGLMadrigal Pharmaceuticals, Inc. | $100.1M |
—MyoKardia, Inc. | $83.2M |
HRTXHeron Therapeutics, Inc. | $70.7M |
CERSCerus Corporation | $63.8M |
—Zymeworks Inc. | $60.6M |
1T7Tricida, Inc. | $58.7M |
BCELAtreca, Inc. | $58.5M |
—DBV Technologies S.A. | $57.3M |
AXSMAxsome Therapeutics, Inc. | $52.3M |
IM8NInsmed Incorporated | $48.5M |
KNSAKiniksa Pharmaceuticals, Ltd. | $43.3M |
RYTMRhythm Pharmaceuticals, Inc. | $41.2M |
KRYSKrystal Biotech, Inc. | $40.9M |
NBIX 2.25 05/15/24Neurocrine Biosciences, Inc. | $39.3M |
—Neoleukin Therapeutics, Inc. | $38.7M |
CCXIEURChemoCentryx, Inc. | $34.5M |
ALLKGUSDAllakos Inc. | $32.7M |
—GW Pharmaceuticals plc | $32.5M |
AUPHAurinia Pharmaceuticals Inc. | $24.7M |
MRUSMerus N.V. | $24.7M |
APLSApellis Pharmaceuticals, Inc. | $24.0M |
ASMBAssembly Biosciences, Inc. | $22.9M |
BCRXBioCryst Pharmaceuticals, Inc. | $21.9M |
—Frequency Therapeutics, Inc. | $21.0M |
ADPTAdaptive Biotechnologies Corporation | $20.7M |
ALKSAlkermes plc | $17.9M |
QUREuniQure N.V. | $16.9M |
BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | $15.6M |
XNCRXencor, Inc. | $12.8M |
URGNUroGen Pharma Ltd. | $12.0M |
PTGXProtagonist Therapeutics, Inc. | $11.9M |
ADAPYAdaptimmune Therapeutics plc | $10.0M |
—Aimmune Therapeutics, Inc. | $9.7M |
—Urovant Sciences Ltd. | $9.2M |
MIRMMirum Pharmaceuticals, Inc. | $8.2M |
RETAEURReata Pharmaceuticals, Inc. | $8.1M |
AGLEUSDAeglea BioTherapeutics, Inc. | $8.0M |
IFRXInflarx N.V. | $6.8M |
ALECAlector, Inc. | $6.8M |
GBYSangamo Therapeutics, Inc. | $6.4M |
—BioDelivery Sciences International, Inc. | $6.2M |
FLGTFulgent Genetics, Inc. | $6.1M |
—Idera Pharmaceuticals, Inc. | $6.1M |
BDQMAlbireo Pharma, Inc. | $6.0M |
HZNPHorizon Therapeutics Public Ltd Co | $5.9M |
HOOKGBPHOOKIPA Pharma Inc. | $5.8M |
OPHTEURIVERIC bio, Inc. | $5.6M |
CABACabaletta Bio, Inc. | $4.6M |
—ArTara Therapeutics, Inc. | $4.6M |
—Millendo Therapeutics, Inc. | $4.4M |
PASGPassage Bio, Inc. | $4.3M |
—Constellation Pharmaceuticals, Inc. | $4.2M |
—Immunomedics, Inc. | $4.2M |
NERVGBPMinerva Neurosciences, Inc. | $4.1M |
—Syros Pharmaceuticals, Inc. | $4.1M |
CPRXCatalyst Pharmaceuticals, Inc. | $4.1M |
—Abeona Therapeutics Inc. | $3.3M |
ANABAnaptysBio, Inc. | $3.3M |
—Evofem Biosciences, Inc. | $3.3M |
—Molecular Templates, Inc. | $3.2M |
NGMUSDNGM Biopharmaceuticals, Inc. | $3.1M |
ORTXUSDOrchard Therapeutics plc | $3.1M |
KRTXKaruna Therapeutics, Inc. | $3.0M |
VSAREURAravive, Inc. | $2.8M |
TPIVDEURMarker Therapeutics, Inc. | $2.8M |
CRNXCrinetics Pharmaceuticals, Inc. | $2.6M |
GLPGGalapagos NV | $2.6M |
XLRNAcceleron Pharma Inc. | $2.4M |
GBTUSDGlobal Blood Therapeutics, Inc. | $2.4M |
—Harpoon Therapeutics, Inc. | $2.4M |
MTNBEURMatinas BioPharma Holdings, Inc. | $2.3M |
APLTApplied Therapeutics, Inc. | $2.2M |
VKTXViking Therapeutics, Inc. | $2.0M |
—bluebird bio, Inc. | $1.8M |
DNLIDenali Therapeutics Inc. | $1.8M |
RCUSArcus Biosciences, Inc. | $1.7M |
—Menlo Therapeutics Inc. | $1.7M |
NTLAIntellia Therapeutics, Inc. | $1.6M |
LPTXEURLeap Therapeutics, Inc. | $1.5M |
—ARYA Sciences Acquisition Corp. | $1.5M |
—Dicerna Pharmaceuticals, Inc. | $1.5M |
—Bellicum Pharmaceuticals, Inc. | $1.2M |
GTHXEURG1 Therapeutics, Inc. | $970K |
Page 1 of 2Next